Clinical Trial Update: Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on AdVince, a recombinant adenovirus, evaluating safety and preliminary efficacy in patients with neuroendocrine tumors. The study spans P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• AdVince

Snippet

Sponsor: Uppsala University | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING